Collection: Pyoderma Gangrenosum Collection
-
Safety Shield Study for ADALIMUMAB
Regular price From €800,00 EURRegular priceUnit price / per -
Clinical Endpoints Study for PYODERMA GANGRENOSUM
Regular price From €2.000,00 EURRegular priceUnit price / per -
Expert mapping Study for PYODERMA GANGRENOSUM
Regular price From €1.500,00 EURRegular priceUnit price / per -
Safety Shield Study for RUXOLITINIB
Regular price From €800,00 EURRegular priceUnit price / per -
Safety Shield Study for THALIDOMIDE
Regular price From €800,00 EURRegular priceUnit price / per -
Safety Shield Study for RILONACEPT
Regular price From €800,00 EURRegular priceUnit price / per -
Safety Shield Study for CYCLOSPORINE
Regular price From €800,00 EURRegular priceUnit price / per -
Safety Shield Study for TACROLIMUS
Regular price From €800,00 EURRegular priceUnit price / per -
Safety Shield Study for METHOTREXATE
Regular price From €800,00 EURRegular priceUnit price / per -
Safety Shield Study for MYCOPHENOLATE MOFETIL
Regular price From €800,00 EURRegular priceUnit price / per -
Safety Shield Study for PREDNISONE
Regular price From €800,00 EURRegular priceUnit price / per -
Safety Shield Study for CANAKINUMAB
Regular price From €800,00 EURRegular priceUnit price / per -
Safety Shield Study for ANAKINRA
Regular price From €800,00 EURRegular priceUnit price / per -
Safety Shield Study for AZATHIOPRINE
Regular price From €800,00 EURRegular priceUnit price / per -
Safety Shield Study for COLCHICINE
Regular price From €800,00 EURRegular priceUnit price / per -
Safety Shield Study for USTEKINUMAB
Regular price From €800,00 EURRegular priceUnit price / per
Explore our exclusive study series
-
Safety Shield Studies
Safety Shield uses AI to streamline pharmacovigilance, reducing specialist workload by 80%...
-
Expert Mapping Studies
Expert Mapping Reports cut screening time by 10 days and reduce failed...
-
Clinical Endpoints Studies
This targeted analysis delivers a robust assessment of clinical endpoints tailored to...